The share price plummeted by 80%. Is the major shareholder of “northeast yaomao” facing a position explosion? The Secretary suddenly became angry

In the evening after the sharp fall of a shares, two pictures were particularly popular.

One is the front page headline of Shanghai Securities News on April 23, 2008. In less than half a year, the market fell from 6124 points to 3000 points. Many netizens said that they did not expect that in the next 14 years, the market would start the “3000 point defense war” again and again.

There’s nothing more to say about this one. Everything is in silence.

Another picture is a dynamic of Changchun High And New Technology Industries (Group) Inc(000661) ‘s secretary in the circle of friends.

After 18:00 on April 25, Changchun High And New Technology Industries (Group) Inc(000661) Board Secretary Zhang Deshen released a circle of friends: “heaven! God! Buddha! Are you blind?”

It is understood that Zhang Deshen shut down after releasing the dynamic. At present, I don’t know what he meant by the dynamic, but many netizens speculated that it was related to the stock price.

On April 25 two years ago, the share price of Changchun High And New Technology Industries (Group) Inc(000661) was still about 300 yuan, and now only 135 yuan is left. Compared with the high of 683 yuan in the past two years, it has fallen by 80%, and the total market value has evaporated by more than 150 billion yuan.

The most annoying thing is that at the end of January this year, affected by the collection policy, Changchun High And New Technology Industries (Group) Inc(000661) fell by the limit for three consecutive trading days. In order to save the stock price, executives collectively increased their holdings. According to the increase price at that time, it has suffered a lot of losses.

major shareholders face position explosion

executives’ maximum floating loss of shares increased by 27%

On January 19, Guangdong Provincial Drug Trading Center issued the document on centralized procurement of diclofenac and other drugs of Guangdong alliance, confirming that recombinant human growth hormone will be included in the centralized procurement of Guangdong alliance, and the centralized procurement will set a ceiling price for recombinant human growth hormone.

As soon as the news came out, Changchun High And New Technology Industries (Group) Inc(000661) share price plummeted for three consecutive trading days. In this case, Changchun High And New Technology Industries (Group) Inc(000661) announced that it would ensure that the mortgagee’s position was not closed by supplementing other property mortgage, supplementary guarantee, prepayment and other supplementary guarantee measures, and the company also rescued the market by repurchasing shares and increasing the holdings of senior executives.

In the follow-up announcement, from December 3, 2021 to January 21, 2022, Changchun High And New Technology Industries (Group) Inc(000661) accumulatively repurchased 2.4732 million shares of the company through centralized bidding transaction through the special securities repurchase account, accounting for 0.61% of the total share capital of the company, of which the highest transaction price was 308.35 yuan / share and the lowest transaction price was 184.36 yuan / share, with a total transaction amount of 600 million yuan (including transaction costs).

On January 21, Changchun High And New Technology Industries (Group) Inc(000661) Chairman Ma Ji, director and general manager Jiang Yuntao, director and Executive Deputy General Manager Ye Peng, director and deputy general manager Wang Zhigang, chairman of the board of supervisors Xie Bing, supervisor Zhao Shuping, deputy general manager Li Xiufeng, deputy general manager and chief financial officer Zhu Xinggong, and Secretary of the board of directors Zhang Deshen increased their holdings of 84700 shares of the company through centralized bidding trading in the securities trading system of Shenzhen Stock Exchange, The average increase price was 184.36 yuan / share.

Boosted by the above news, on January 24, Changchun High And New Technology Industries (Group) Inc(000661) although opened significantly lower, it did not open at the limit price as in the previous two trading days. Although the limit was once lower, the limit was quickly opened and fluctuated weakly throughout the day.

However, Changchun High And New Technology Industries (Group) Inc(000661) ‘s share price did not rebound from the bottom, but kept looking for the bottom. As of the closing on the 25th, the increased shares held by many executives such as the Secretary of the board of directors had lost 26%.

It is worth noting that this time, Changchun High And New Technology Industries (Group) Inc(000661) of the major shareholders once again faced a position explosion. According to the data, the stock pledge of 11 million shares of Changchun High And New Technology Industries (Group) Inc(000661) Chaoda Investment Co., Ltd., the major shareholder of Changchun High And New Technology Industries (Group) Inc(000661) has fallen by nearly 70%, close to bursting.

It’s very disturbing to put it on the secretaries of any company

centralized mining and epidemic suppression

Changchun High And New Technology Industries (Group) Inc(000661) first quarterly report or unsatisfactory

how big is the impact of centralized purchase

It is understood that on March 10, the official website of Guangdong Pharmaceutical Trading Center announced the results of the proposed winning of centralized volume procurement (the first batch) in 276 pharmaceutical alliance regions such as diclofenac. The three types of human growth hormone (powder injection) for injection of Kinsey pharmaceutical were selected for centralized collection in Guangdong alliance area, with specifications of 2.5iu, 10iu and 4iu respectively. The price of each proposed winning product is 209344 yuan, 605004 yuan and 30 yuan respectively. For the above three specifications of powder injections, the pre procurement volume in the first year of the procurement period is 22535, 25163 and 245436 respectively.

According to rough calculation, the total sales volume corresponding to the reported volume of the above three types of powder injections is 9.6302 million yuan.

During the investigation of Boshi fund and other institutions on March 17, Changchun High And New Technology Industries (Group) Inc(000661) revealed that “among the growth hormone products of Kinsey pharmaceutical, powder injection accounts for about 10%. Based on the income of 8.198 billion yuan in the annual report of 2021, the income of powder injection is about 800 million yuan.

Changchun High And New Technology Industries (Group) Inc(000661) in the institutional research, he said, “among the growth hormone products of kinsay pharmaceutical, powder injection accounts for about 10%; water injection accounts for more than 70%; long-term water injection accounts for more than 18%. Among them, the income of long-term water needle increased by more than 110%.

I thought that Changchun High And New Technology Industries (Group) Inc(000661) gave up the bid winning water injection, and the low-end powder injection at the bid winning price was an adjustment in sales strategy.

However, on March 15, Changchun High And New Technology Industries (Group) Inc(000661) lowered the price of long-acting water needle. For example, the price of hanging net in Qinghai was adjusted from 5600 yuan to 3500 yuan, a decrease of 37.5%.

Not only the products with high profit and high growth are reduced in price, but also the production of Changchun High And New Technology Industries (Group) Inc(000661) some production lines are affected by the Jilin epidemic.

On April 20, Changchun High And New Technology Industries (Group) Inc(000661) said on the interactive platform that subsidiary kinsay Pharmaceutical at present, the production line of main products has been fully resumed, and the overall resumption of production will continue to be promoted in the future subsidiary Changchun Bcht Biotechnology Co(688276) has implemented closed management since the outbreak of the epidemic in Changchun to maintain the continuity of production and the stability of product supply. Huakang pharmaceutical, a subsidiary, is located in Dunhua City, Jilin Province and is less affected by the epidemic in Changchun.

It is understood that Changchun High And New Technology Industries (Group) Inc(000661) will release the first quarterly report on April 28. So far, most market participants are not optimistic about its performance in the first quarter.

- Advertisment -